Side-by-side comparison of AI visibility scores, market position, and capabilities
SF open-source AI-first workflow automation at $1.7M ARR Dec 2024 with 450+ integrations and self-hosted option; YC $1.55M competing with Zapier and n8n for compliance-conscious teams needing MCP/Claude/GPT-4 automation pipelines.
Activepieces is a San Francisco-based open-source workflow automation platform — backed by Y Combinator with $1.55 million raised from ByTheTower, Forward VC, Fundamental VC, Kima Ventures, and Soma Capital in November 2024 — providing teams with an AI-first business process automation alternative to Zapier, Make.com, and Workato through a self-hostable, MIT-licensed platform with 450+ integrations, native AI agent support (GPT-4, Claude, Model Context Protocol), and a managed cloud version. Founded in 2022 and reaching $1.7 million in annual revenue by December 2024 with a team of 11-19 employees, Activepieces has differentiated through its open-source model — allowing companies with data compliance requirements (GDPR, HIPAA, SOC 2) to run the entire automation infrastructure on their own servers rather than routing sensitive data through third-party SaaS automation platforms.
Kong-acquired (2019) open-source API testing and development platform with 1M+ users; Insomnia 10 added AI Runner, competing with Postman for the API client developer tooling market.
Insomnia is an open-source API development and testing platform that provides developers with a powerful client for designing, debugging, and testing REST, GraphQL, SOAP, and WebSocket APIs — offering an intuitive interface for crafting API requests, inspecting responses, organizing API collections, and writing automated tests without the complexity of commercial alternatives. Founded in 2014 by Gregory Schier in Victoria, Canada, Insomnia was acquired by Kong (the leading API management company) in October 2019 and has grown to over 1 million users as of September 2024.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.